4 September 2025 - - Sol-Gel Technologies announced today that on 27 August 2 2025 Health Canada issued a Notice of Compliance for Epsolay for the treatment of inflammatory lesions of rosacea in adults.

This approval comes as a result of Sol-Gel’s partnership with Searchlight Pharma, Sol-Gel’s exclusive licensee for commercialising Epsolay in the Canadian market.

Read Sol-Gel Technologies press release